SCHEMBL6282956

SCHEMBL6282956

CCOCc1nc2c(N)nc(C)c(C)c2n1CCC1CCN(S(=O)(=O)c2ccc(/N=N/c3ccc(N(C)C)cc3)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 7/20 0.36
TLR8 Q9NR97 6/20 0.35
NUDT1 P36639 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
MAPT P10636 3/20 0.32
NPC1 O15118 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32
CA9 Q16790 1/20 0.32
LMNA P02545 3/20 0.31
ALDH1A1 P00352 4/20 0.31
KDM4E B2RXH2 1/20 0.31
ADRB2 P07550 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TGFBR1 P36897 1/20 0.31
CD4 P01730 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282958 1.00 TLR7 (0.36) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6783346 0.88 TLR7 (0.38) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6780086 0.86 TLR7 (0.41) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6779825 0.86 MEN1 (0.40) TLR7TLR8MEN1KMT2AMAPT
SCHEMBL6780432 0.83 KMT2A (0.43) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6284763 0.83 ALDH1A1 (0.39) TLR7TLR8NUDT1ALDH1A1GAA
SCHEMBL6780316 0.82 TLR7 (0.38) TLR7TLR8NUDT1NPC1RAB9A
SCHEMBL6281876 0.82 TLR7 (0.38) TLR7TLR8NUDT1LMNA
SCHEMBL6779180 0.81 KDM4E (0.40) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6780878 0.79 TLR7 (0.36) TLR7TLR8NUDT1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696465-B2 INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2004-02-24 US claimed
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 US disclosed
EP-1453829-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-08 EP disclosed
US-20040147533-A1 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-29 US disclosed
US-6696465-B2 INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2004-02-24 US disclosed
US-20040019076-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-29 US disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147533-A1 Sulfonamido substituted imidazopyridines IRF3, EIF2AK2, MYD88 TLR7 52/4885TLR8 62/4885NUDT1 860/4885
US-20040019076-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES IRF3, EIF2AK2, MYD88 TLR7 52/4885TLR8 62/4885NUDT1 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.